By staff writers

November 7, 2019 -- Women's imaging vendor Hologic finished strong in its 2019 fiscal year, with the company's revenue accelerating in the fourth quarter at the highest rate of the year. However, charges related to its Cynosure medical aesthetics business pushed the company into the red for the year.

For the fourth quarter (end-September 28), Hologic finished with revenue of $865.8 million, up 6.4% from sales of $813.5 million in the same period of 2018. The company's net income for the quarter was $39.9 million, which included a noncash impairment charge of $79.2 million. The company's net income was $50.5 million in the fourth quarter of 2018.

Hologic reported that its Breast Health segment turned in revenue of $342.6 million, up 6.3% after currency adjustment from sales of $322.2 million in the fourth quarter of 2018. The company's Diagnostics business reported fourth-quarter revenue of $306.8 million, up 6.2% from sales of $288.9 million in the same period of 2018, which Hologic said represented "robust" growth.

For the year, Hologic recorded revenue of $3.367 billion, compared with $3.218 billion for fiscal 2018. The company posted a loss for the year of $40.2 million, compared with a loss of $111.3 million in 2018. The 2019 numbers include asset impairment charges of $523 million, compared with impairment charges of $731.7 million in fiscal 2018. Both charges were related to write-downs for the company's Cynosure business, a medical aesthetics firm that Hologic bought in 2017.

Revenue up in Hologic's Q3
Powered by growth in its Diagnostics and Breast Health units, women's imaging vendor Hologic increased total revenue in the company's third fiscal quarter.
FDA clears 2 Hologic tests for yeast infections
The U.S. Food and Drug Administration (FDA) has cleared two diagnostic tests from Hologic for diagnosing vaginitis, or yeast infections, the company announced...
Hologic's ThinPrep Genesis slide processor gets CE Mark
Hologic has received the CE Mark for its ThinPrep Genesis processor for cytology slide and molecular test preparation, giving the company the go-ahead...
FDA gives nod to Hologic assay for STI bacterium
The U.S. Food and Drug Administration (FDA) has allowed the marketing of a new assay by Hologic for detecting Mycoplasma genitalium, a type of...

Copyright © 2019

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.